504 related articles for article (PubMed ID: 9885371)
1. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
4. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA
Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740
[TBL] [Abstract][Full Text] [Related]
5. Topotecan: a review of its efficacy in small cell lung cancer.
Ormrod D; Spencer CM
Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
[TBL] [Abstract][Full Text] [Related]
6. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
Wall JG; Burris HA; Von Hoff DD; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
[TBL] [Abstract][Full Text] [Related]
7. An overview of the clinical pharmacology of topotecan.
Dennis MJ; Beijnen JH; Grochow LB; van Warmerdam LJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-12-S5-18. PubMed ID: 9122737
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
[TBL] [Abstract][Full Text] [Related]
9. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
Scarfone G
Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
[TBL] [Abstract][Full Text] [Related]
10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
11. [Topotecan: a new field of use].
Ferrari S; Danova M
Tumori; 1999; 85(6 Suppl 1):S23-8. PubMed ID: 10786197
[TBL] [Abstract][Full Text] [Related]
12. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
15. [Preclinical pharmacology and clinical uses of topotecan].
Del Tacca M; Di Paolo A; Danesi R
Tumori; 1999; 85(6 Suppl 1):S3-11. PubMed ID: 10786194
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
[TBL] [Abstract][Full Text] [Related]
17. Review of phase I clinical studies with topotecan.
Rowinsky EK; Verweij J
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
19. Clinical status and optimal use of topotecan.
Takimoto CH; Arbuck SG
Oncology (Williston Park); 1997 Nov; 11(11):1635-46; discussion 1649-51, 1655-7. PubMed ID: 9394364
[TBL] [Abstract][Full Text] [Related]
20. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
Herzog TJ
Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]